Introduction
Transfer and expression of cytokine genes into tumor cells is now regarded as a valuable approach for investigating antitumor activities of cytokines in experimental models. [1] [2] [3] [4] Numerous studies have demonstrated that the injection of tumor cells genetically modified for the constitutive expression of cytokines (cytokine gene-engineered cells) into syngeneic immunocompetent mice results in tumor rejection by activation of host-dependent antitumor responses. [4] [5] [6] [7] When used as a vaccine, cytokine gene-engineered cells induce a strong tumor specific immune memory that inhibits a subsequent challenge with wild-type parental cells. [5] [6] [7] In these experimental models, the achievement of a local critical concentration of cytokines is essential to determine a rapid and potent
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inflammatory reaction which overcomes the suppressor factors induced by the tumor. 2 Among the immune elements involved in this process have been identified either nonspecific cells (neutrophils, eosinophils, macrophages, large granular lymphocytes), or specific CD4 and CD8 lymphocytes, these last playing a relevant role in the acquisition of immune memory against antigens of tumor cells. 2, [5] [6] [7] In fact, a systemic immunity directed against the unmodified tumor is elicited or potentiated after rejection or vaccination with the cytokine-secreting tumor cells.
The experiments performed until now have clearly demonstrated that the efficacy of cancer therapy with cytokine gene-engineered tumor cells is dependent on the immunocompetence of the host. The rejection of tumors was strictly related to the immune effectiveness of mice and no protection against tumor challenge was obtained in physically or chemically immunosuppressed host. 2, 8 It has been widely demonstrated that a progressive immune deterioration is present during aging. [9] [10] [11] The immune impairment is mainly due to the age-dependent thymic involution which determines a defect of both T cell-mediated and T cell-dependent functions. 10, 12 Thus proliferation to mitogenic lectins and alloantigens, the generation of cytolitic effector cells, delayed-type hypersensitivity, primary and secondary antibody responses and the production of lymphokines required to activate other immune components are diminished in the aged. 9, 10, 13 Instead, more preserved is the function of nonspecific immune cells, such as polymorphonuclear leukocytes, macrophages and NK cells. 9, [13] [14] [15] [16] The age-related decline in immune potential has been cited as a contributing factor to neoplasia. 13 Since over half of all cancers are diagnosed in aging and the elderly population is rapidly expanding, it is relevant to obtain a better understanding of the influence an aging immune system has on cancer growth and to check whether immunogene therapy of cancer may be well functioning also in old age to provide a rationale for the development of immunotherapeutic regiments for the elderly. 17 The aim of this study was to evaluate whether the inoculation of adenocarcinoma cells engineered to release IL-2 in old mice causes an immune activation which results in tumor rejection and induction of specific immune memory as occurs in young animals. Among the various cytokines we chose IL-2 for several reasons. First, IL-2 is a growth promoting cytokine that regulates the function of various cells that are involved in cellular and humoral immunity. 18 It participates in T and B lymphocyte activation, induction of NK and LAK cell activity, boosting of phagocytosis and cytotoxicity of polymorphonuclear leukocytes and macrophages. [18] [19] [20] [21] Second, IL-2 production is reduced in aging and the decline in IL-2 production has been shown to parallel the age-related decrease in immunologic function. 22 Third, both in vitro and in vivo experimental models have demonstrated that IL-2 administration partially or completely restores some of the immune functions that decline during aging.
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Results
In vitro induction of proliferative and cytotoxic responses The ability of TS/A p.c., and a low (B1.30), an intermediate (B6.3600), and a high (B4.6000) IL-2-releasing clones to induce proliferative and cytotoxic responses in spleen cells or lymph node cells from young or old Balb/c mice was evaluated in 5-day mixed lymphocyte-tumor culture (Tables 1 and 2 ). As shown in Table 1 , TS/A p.c. elicited a small proliferative response whereas either B1.30, B6.3600, or B4.6000 IL-2 transfected clones induced strong proliferation of spleen cells from both young and old mice. Those elicited by B6.3600 or B4.6000 were highest in both ages.
As shown in Table 2 , low cytotoxic activity was generated culturing spleen or lymph node cells from young or old mice in the presence of TS/A p.c. By contrast, both B6.3600 and B4.6000 transfected clones elicited high cytotoxic responses in both ages of mice. The values of cytotoxicity were higher in cultures conducted in the presence of B4.6000 than B6.3600 tumor cells. Cytotoxicity was always lower in old than young mice (P Ͻ 0.05).
Oncogenicity of the transfected clones
In order to evaluate whether the secretion of IL-2 by TS/A-IL2 clones affects the in vivo ability to form a tumor, Balb/c mice were challenged s.c. in the left inguinal flank with 1 × 10 5 cells, a dose 2.5 times higher than the minimal 100% tumor-inducing dose of TS/A parental cells. All mice challenged with either TS/A p.c. or B1.30 cells developed tumors with a progression pattern similar in young and old ages (Figure 1 ). Both the B6.3600 and the B4.6000 cells were rejected by 100% of both young and old mice ( Figure 1 ). B6.3600 cells were rejected more rapidly than B4.6000 clone in both ages of mice. A slower but not statistically significant kinetics of rejection of both TS/A clones was observed in old than young animals.
Morphological analysis of growth and rejection patterns of TS/A parental cells and TS/A-IL-2 clones
To investigate reaction mechanisms associated with IL-2 releasing cell challenge, young or old mice were killed 5 and 10 days after challenge. As shown in Figure 
c. (a), or B1.30 (b), B6.3600 (c), or B4.6000 (d) TS/A-IL2 clones. The mean tumor diameter was evaluated twice a week measuring the tumor masses with calipers in the two perpendicular diameters.
granulation tissue infiltrated by reactive cells (Figure 2c ). At day 10, neoplastic cells were no longer detectable and a granulation tissue rich of reactive cells substituted the tumor (Figure 2d and e). The reaction pattern was similar in old and young mice.
The cell composition of the reactive infiltrate in the tumor area was evaluated by immunohistochemistry (Table 3) . Both in B6.3600 and B4.6000-challenged young mice, a massive infiltrate of neutrophils and macrophages with a minor number of CD4 + and CD8 + lymphocytes was found. In old mice, neutrophils and macrophages were also the main cells infiltrating the tumor, though they were less represented than in young animals. Both CD4 + and CD8 + lymphocytes were scarcely present in peri-and intratumoral infiltrate in comparison with young animals, and particularly in old mice challenged with B4.6000 cells in which CD4
+ and CD8 + lymphocytes were nearly absent.
Analysis of apoptosis of tumor cells in situ through TUNEL assay
The presence of apoptosis in parental or IL2 gene-transfected TS/A tumor cells was than evaluated in situ using the TUNEL methodology on day 5 after tumor challenge. As shown in Figure 3b , a great number of apoptotic cells was found in B4.6000-challenged young mice in the tumor area. No evidence of apoptosis was present in old mice injected with TS/A p.c. (Figure 3c ). Similar data were obtained in TS/A p.c.-injected young mice. As shown in Figure 3d , a lower number of apoptotic cells was found in B4.6000-challenged old mice in comparison with young animals inoculated with the same TS/A clone ( Figure 3b) . A strong positivity was obtained in DNase-treated tumor cells which served as positive control (data not shown).
Immunogenicity of the transfected clones
To test whether the rejection of tumor clones producing IL-2 induced a tumor specific immune memory, mice with no tumors after the challenge with B6.3600 and B4.6000 clones performed 30 days earlier received a lethal challenge of the TS/A p.c. (Figure 4 ). Good protection was found in young mice that had injected with the B4.6000 clone since 90% of them rejected the TS/A p.c. Rejection was observed only in 30% of young mice that were challenged with the B6.3600 clone. In old mice, no protection was found in animals that had been injected with B4.6000 clone, whereas only 10% of mice which received B6.3600 cells were able to reject TS/A p.c.
Thymus graft and adoptive transfer of T lymphocytes in old mice
The possibility to induce a tumor specific immune memory against TS/A p.c. in old mice was evaluated through the graft of a young thymus or the adoptive transfer of young memory T lymphocytes to old mice.
Nineteen-month-old mice were grafted with a young thymus under the kidney capsule and killed 2 months later. To verify the successful thymic engraftment, old thymus-grafted mice were checked for the presence of the implanted thymus at the time of death. We then investigated whether the TS/A specific immune memory could be induced in these mice. As shown in Figure 5a mice with a kinetics similar to that observed in agematched controls. The challenge with TS/A p.c. 30 days after B6.3600 cells developed tumors with a progression pattern similar to that of old control mice (Figure 5b ). The adoptive transfer to old mice of immune memory T cells established after the rejection of TS/A-IL-2 cells in young animals was then investigated. The transfer of Thy 1.2 positive spleen lymphocytes from young mice challenged 30 days before with B6.3600 or B4.6000 clones did not protect old mice against the challenge with TS/A p.c. (Table 4) . On the contrary, Thy 1.2 positive lymphocytes from both B6.3600 and B4.6000-challenged young Gene Therapy mice, significantly protected untreated young animals from a subsequent challenge with TS/A p.c. (Table 4) .
Discussion
Experimental studies in immunocompetent animal models have demonstrated that gene therapy and vaccination with cytokine gene-engineered tumor cells represent an efficacious approach to induce antitumor immunity. [1] [2] [3] [4] [5] [6] [7] The rejection of tumors and the induction of specific immune memory obtained in these models have been strictly related to the effectiveness of the immune system and no protection against tumor challenge has been observed in the physically or chemically immunosuppressed host. 2, 8 An immune dysfunction, mainly involving thymusdependent functions, occurs during aging in both animals and humans. [9] [10] [11] This age-related immune impairment has been associated with an age-dependent increase in cancer disease. 13 Despite the constant rising fraction of aged individuals in the population and therefore the importance of cancer research in aged patients, only few data have been devoted to the effect of age on tumor progression and the influence an aging immune system has on cancer growth and on the possibility of applying immunogene therapy of cancer in the elderly.
In the present study, we report for the first time that the inoculation of adenocarcinoma cells engineered to release IL-2 in old mice is effective in inducing an inflammation-like reaction which results in tumor rejection but is not able to elicit a tumor-specific immune memory. Moreover, the immune reconstitution of old mice with the graft of a young thymus or the adoptive transfer of young memory T lymphocytes did not confer immune memory against TS/A adenocarcinoma parental cells to old mice.
As it has been previously shown in young immunocompetent mice, [6] [7] [8] our results demonstrate that the in vivo inoculation of TS/A p.c. is not able to elicit a protective immune response in syngeneic animals while the local release of IL-2 from IL-2-engineered tumor cells induces nonspecific immune effectors which leads to tumor rejection. The prompt rejection of TS/A-IL-2 clones was due to inflammation-like reaction associated with neutrophils and macrophages that infiltrate the tumor mass and kill tumor cells. We found that these mechanisms were operating well in both young and old mice as shown by the 100% success in TS/A-IL-2 tumor cell rejection in both ages of animals. These results are in line with previous data of immune effectiveness in aging, showing that the function of nonspecific immune effectors, such as polymorphonuclear leukocytes and macrophages, is well preserved in later life. 13, 14 In the classic mouse experimental models previously performed, the immune activation induced by IL-2-releasing cells was able to overcome their oncogenic capacity inducing a systemic and long-lasting tumor-specific immune memory against TS/A p.c. [6] [7] [8] It has been shown that the mechanisms responsible for inhibition of tumor growth are not the same as those required for immune memory. 2 In the case of TS/A-IL-2 cells, it was shown that these cells are rejected because of direct killing by activated neutrophils and macrophages whereas the induction of memory to a subsequent parental-tumor challenge depends on CD4 + T cells and is mediated by CD8 + T cells. 8 With regards to young immunocompetent mice, our data agree with previous studies demonstrating that TS/A-IL-2 clones induce an immune activation in young mice which results in the acquisition of tumor specific immune memory. 8 We report for the first time that TS/A-IL-2 clones are not able to induce a tumor specific immune memory in old mice.
Figure 5 Inability of B6.3600 cells to induce protection against a challenge of TS/A p.c. in thymus grafted old mice. (a) Balb
Aging has been associated with an immune derangement, particularly evident at the level of the thymusdependent immunity. 10, 12 Thus, the proliferation and the cytotoxicity of T cells, the cytokine secretion, and the capacity to mount humoral or cell-mediated responses against novel antigens, are all impaired in old age. [9] [10] [11] [12] A major part of the basis for the loss of T cell function is the reduced ability of the T cell to respond to activation signals that are transmitted through the membrane binding of specific stimulatory signals. 24 However, numerical changes may also have a role in the aging of the immune network since a significant decrease in the ratio of naive to memory T cells has been reported in aging, thus demonstrating a reduced representation of unprimed T cells able to induce primary responses. 25 Our data on the ineffectiveness of TS/A-IL-2 cells to elicit a tumor-specific immune memory in old mice may be explained, at least in part, by the general impairment of the T cell compartment described above. In order to verify this possibility we tried to recover the defect in memory acquisition by rejuvenating T cell compartment through the graft of a young thymus or the adoptive transfer of young memory T lymphocytes to old mice. The efficacy of thumus graft in recovering various immunologic and nonimmunologic functions in old mice has been demonstrated. 26, 27 In our model, the thymus graft was not able to confer tumor specific immune memory to old mice. Since we checked the successful thymic engraftment either by looking for the presence of thymus at the time of death or by evaluating the recovery of some immune parameters (data not shown), we thought that the failure of thymus transplantation might be related to a defect in the differentiation of 'young' thymocytes into mature T cells in the 'old' recipient. To evaluate this possibility, we transferred young memory T lymphocytes obtained from animals previously challenged with TS/A-IL-2 cells to old mice. Also this approach failed in conferring tumor specific immune memory on old mice. The fact that T cells per se do not seem to be the only cause of immune memory deficiency in old age was also suggested in a previous study in which it was demonstrated that the unresponsiveness of spleen cells from aged mice to pneumococcal vaccine was not due to an intrinsic lymphocyte defect but resulted from an accessory cell deficiency. 28 These results suggest that other factors might be responsible for the age-associated defect in memory acquisition and that an impairment in antigen presentation 28, 29 or the presence of suppressor T cell clones protective against tumor cells 13 might be involved and have to be evaluated in further investigations. The evaluation of in situ apoptosis after challenge of TS/A-IL-2 cells, showing a lower number of apoptotic tumor cells in old in comparison with young mice, deserves particular attention. In fact, recent evidence has demonstrated that apoptosis but not necrosis is required for the generation and packaging of immunogenic material for delivery to antigen presenting cells and then for antigen presentation to T cells. 30 Furthermore, antigen presenting cells that had phagocytosed apoptotic tumor-derived cells but not nonapoptotic tumor cell extracts induce effective specific long-term protection from parental tumor challenge. 31 In the light of these findings, we may suspect that the lower apoptosis observed in old mice may result in a defect of tumor antigen presentation to antigen presenting cells and then in the absence of memory acquisition.
In conclusion, our data demonstrate the ineffectiveness of vaccination with cytokine gene-engineered tumor cells in old mice suggesting the existence of a defect in the passage from an inflammation-like reaction to specific immunity in old age that disables previously nonimmunogenic tumors to generate an effective immunogenic signal. The application of gene therapy and vaccination in aging requires further studies in order to design and test protocols effective also in advanced periods of life.
Materials and methods
Mice Male Balb/c (H-2 d ) inbred mice were used in two groups, young (2-3 months) and old (21-24 months). The mice were housed in plastic nongalvanised cages (4-6 mice per cage) and fed with standard pellet food (Harlan, Milano, Italy) and tap water ad libitum. The animals were maintained at constant temperature (20 ± 1°C) and humidity (50 ± 5%) on a 12 h light/12 h dark cycle.
) is a highly aggressive and poorly immunogenic cell line established from the first in vivo transplant of a moderately differentiated mammary adenocarcinoma that spontaneously arose in a 20-month-old multiparous Balb/c mouse. 32 Several vials of the eighth in vitro passage of the TS/A parental cells (TS/A p.c.) were stored in liquid nitrogen before thawing and cultured by one or two passages in vitro in RPMI 1640 medium (Gibco BRL, Life Technologies, Italy) supplemented with 10% FCS, 50 g/ml gentamicin, 2 mm glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin (all from Gibco BRL). Confluent monolayers ( IL-2 gene transfection and IL-2 titration TS/A parental cells, transfected with the expression vectors BCMG neo-mIL2 containing the neomycin-resistance gene and the murine IL-2 cDNA by electroporation using a Bio-Rad laboratory apparatus as previously described, 8 were a generous gift of Dr G Forni from the University of Turin, Italy. IL-2-releasing TS/A clones were cultured in selective medium containing 300 g/ml geneticin (G418; Sigma Chemical, St Louis, MI, USA). The concentration of IL-2 produced by different clones was evaluated by a Pharmingen's cytokine ELISA protocol by using a purified rat antimouse IL-2 MoAb (capture antibody), a biotinylated rat antimouse IL-2 MoAb (detecting antibody) and a recombinant mouse IL-2 for standard sample preparations (Pharmingen, San Diego, CA, USA). Three clones of TS/A cells were used producing low (30 U, B1.30), intermediate (3600 U, B6.3600) or high (6000 U, B4.6000) IL-2.
In vitro cytotoxicity and proliferation tests Cytotoxic effector cells were generated by culturing for 5 days 1 × 10 7 responder spleen cells or pool of lymphocytes from axillary, inguinal, and mesenteric lymph nodes and 0.5 × 10 6 stimulator tumor cells treated with 60 g/ml of mitomycin-C (Mit-C, Sigma) for 30 min at 37°C. Cytotoxicity was assessed in a 48-h The values were expressed as lytic units (LU 20 /10 7 ) calculated by using a computational method. 33 One LU corresponds to the number of effector cells required to produce 20% of specific lysis.
Proliferation was evaluated by culturing in triplicate spleen cell alone, or with Mit-C-stimulator cells at an effector:target ratio of 20:1, for 5 days in flat bottomed 96-well microtest plates. Each well was pulsed with 1 Ci of 3 H-TdR for 18 h before the harvesting. 3 H-TdR uptake was assayed in a liquid scintillation spectrophotometer and the data were expressed as total c.p.m. less spontaneous uptake of responder and stimulator cells.
Morphologic analysis
Groups of three mice were killed 5 and 10 days after tumor challenge. The flanks were gently dissected and the presence of tumor masses, as well as the enlargement of lymph nodes, recorded. Tumor tissues were embedded in Tissue-Tek OCT compound (Miles Inc, Elkart, IN, USA), frozen in liquid nitrogen and preserved at −80°C until sectioning. For histological evaluation, tissues were sectioned at 4 m, fixed in 4% paraformaldehyde (Carlo Erba, Milan, Italy), and stained with hematoxylin-eosin solutions (Polysciences, Warrington, PA, USA). Neutrophils were characterized by segmented or doughnut nuclei and clearly distinguishable from eosinophils by the absence of eosinophilic granules. For immunohistochemistry, 4 m cryostat sections were fixed in acetone (at −20°C) for 5-10 min and washed twice with PBS. Endogenous peroxidase was quenched with 0.1% hydrogen peroxide in methanol for 5 min. The slides were washed in PBS and incubated in normal blocking serum for 20 min to prevent nonspecific binding. After that, the slides were washed again and immunostained with purified rat antimouse moAb to CD8a (Ly-2), CD4 (L3T4), MAC-3 and Ly-6G (Gr-1) (Pharmingen) for 30 min at room temperature. Antibody binding was localized using an anti-rat biotinylated secondary antibody, avidin-conjugated horseradish peroxidase, and diaminobenzidine substrate, contained within a Santa Cruz ABC Immunostain System (Santa Cruz Biotechnology, CA, USA). Staining with isotype-matched rat IgG was performed as a negative control. Slides were counterstained with hematoxylin. Quantitative studies of the immunohistochemically stained reactions were performed by evaluating five randomly chosen fields in each sample. Individual cells were counted under a ×400 microscopic field (×40 objective and ×10 ocular lens: 0.180 mm 2 per field).
Detection of in situ cell death For in situ staining of apoptotic cells, TdT-catalyzed DNA nick end labeling (TUNEL) method was performed using a kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. Detection was done with diaminobenzidine substrate. Negative controls without terminal transferase were included. Positive controls were included treating tumor cells with DNase I (80 U/ml, 10 min, room temperature, Sigma) to induce DNA strand breaks. Sections were counterstained with hematoxylin. 
Statistical analysis
All in vivo experiments were performed two or three times with groups of five to eight mice, and the results were cumulated as they gave analogous results. Results are expressed as the mean ± s.d. Statistical significance was determined by using analysis of variance (ANOVA). When significant differences were found statistical analysis was made by Student-Newman-Keuls test for multiple comparison. Differences were considered statistically significant when P Ͻ 0.05. The significance of differences in tumor-free animals was determined by Chi-square test.
